Whooping cough in 2014 and beyond: An update and review

Chest

Volumn 146, Issue 1, 2014, Pages 205-214

  Hartzell, Joshua D ^a   Blaylock, Jason M ^a  

^a Walter Reed National Military   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; COTRIMOXAZOLE; MACROLIDE; PERTUSSIS VACCINE;

ANTIBODY DETECTION; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; CLINICAL FEATURE; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INCIDENCE; PERTUSSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

COMMUNICABLE DISEASES; DISEASE OUTBREAKS; HUMANS; VACCINATION; WHOOPING COUGH; WORLD HEALTH;

EID: 84903822052     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2942     Document Type: Article

References (99)

1. Guiso N. Bordetella pertussis: why is it still circulating? J Infect. 2014;68(suppl 1):S119-S124.
2. Centers for Disease Control and Prevention. Division of Bacterial Diseases. 2012 Final pertussis surveillance report. Centers for Disease Control and Prevention website. http://www.cdc.gov/pertussis/downloads/pertussis- surveillance-report.pdf.UpdatedOctober18,2013.AccessedNovember12,2013.
3. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60 (1): 13-15.
4. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged, 12 months Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60 (41): 1424-1426.
5. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diph theria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older-Advisory Committee on Immu nization Practices (ACIP), 2012. M MWR Morb Mortal Wkly Rep. 2012; 61 (25): 468-470.
6. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013; 62 (7): 131-135.
7. Cherry JD, Tan T, Wirsing von König CH, et al. Clinical defi nitions of pertussis: summary of a Global Pertussis Initiative roundtable meeting, February 2011. Clin Infect Dis. 2012; 54 (12): 1756-1764.
8. Pertussis (whooping cough): surveillance and reporting-case defi nition. Centers for Disease Control and Prevention website. http://www.cdc.gov/ pertussis/surv-reporting.html#case-definition.UpdatedNovember4,2013. AccessedDecember13,2013.
9. Watanabe M, Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti Infect Th er. 2004; 2 (3): 447-454.
10. Zouari A, Smaoui H, Brun D, et al. Prevalence of Bordetella pertussis and Bordetella parapertussis infections in Tunisian hospitalized infants: results of a 4-year prospective study. Diagn Microbiol Infect Dis. 2012; 72 (4): 303-317.
11. Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis Ohio, 2010-2011. Clin Infect Dis. 2013; 56 (3): 322-331.
12. Zhang X, Weyrich LS, Lavine JS, Karanikas AT, Harvill ET. Lack of cross-protection against Bordetella holmesii aft er pertussis vaccination. Emerg Infect Dis. 2012; 18 (11): 1771-1779.
13. Kamiya H, Otsuka N, Ando Y, et al. Transmission of Bordetella holmesii during pertussis outbreak, Japan. Emerg Infect Dis. 2012; 18 (7): 1166-1169.
14. Miranda C, Wozniak A, Castillo C, et al. Presence of Bordetella holmesii in an outbreak of pertussis in Chile [In Spanish]. Rev Chilena Infectol. 2013; 30 (3): 237-243.
15. Mooi FR, Bruisten S, Linde I, et al. Characterization of Bordetella holmesii isolates from patients with pertussis-like illness in Th e Netherlands. FEMS Immunol Med Microbiol. 2012; 64 (2): 289-291.
16. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine. 2009; 27 (43): 6034-6041.
17. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med. 2013; 368 (6): 583-584.
18. Hegerle N, Paris AS, Brun D, et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Micro biol Infect. 2012; 18 (9): E340-E346.
19. Bodilis H, Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis. 2013; 19 (3): 471-474.
20. Hewitt M, Canning BJ. Coughing precipitated by Bordetella pertussis infection. L ung. 2010; 188 (suppl 1): S73-S79.
21. Wendelboe AM, Njamkepo E, Bourillon A, et al; Infant Pertussis Study Group. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007; 26 (4): 293-299.
22. Immunization surveillance, assessment, and monitoring: pertussis. World Health Organization website. http://www.who.int/immunization-monitoring/ diseases/pertussis/en/.PublishedJuly23,2013.AccessedNovember23,2013.
23. Black RE, Cousens S, Johnson HL, et al; Child Health Epi demiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010; 375 (9730): 1969-1987.
24. Gabutti G, Rota MC, Bonato B, et al. Hospitalizations for pertussis in Italy, 1999-2009: analysis of the hospital discharge database. Eur J Pediatr. 2012; 171 (11): 1651-1655.
25. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005; 24 (suppl 5): S10-S18.
26. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis. 2003; 3 (7): 413-418.
27. Th eodoridou M, Dargenta G, Aptouramani M, et al. Pertussis epidemiology in Greece and emerging risk groups during the vaccination era (1980-2008). Adv Prev Med. 2012;2012:303846. doi:10. 1155/2012/303846.
28. Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007; 298 (18): 2155-2163.
29. Pertussis (whooping cough):outbreaks.Centers for Disease Control and Prevention website.http://www. cdc. gov/pertussis/outbreaks. html. Published September 12, 2013. Accessed November 12, 2013.
30. Armed Forces Health Surveillance Center (AFHSC). Pertus sis diagnoses among service members and other benefi cia ries of the U. S. Military Health System, January 2005-June 2012. MSMR. 2012; 19 (8): 14-17.
31. Centers for Disease Control and Prevention (CDC). Pertussis epidemicWashington, 2012. MMWR Morb Mortal Wkly Rep. 2012; 61 (28): 517-522.
32. Centers for Disease Control and Prevention (CDC). Schoolassociated pertussis outbreakYapavai county, Arizona, September 2002-February 2003. MMWR Morb Mortal Wkly Rep. 2004; 53 (10): 216-219.
33. Centers for Disease Control and Prevention (CDC). Use of mass Tdap vaccination to control an outbreak of pertus sis in a high schoolCook County, Illinois, September 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2008; 57 (29): 796-799.
34. Wall R, Bell A, Th eobald J. Pertussis (whooping cough) epidemiology in Waikato, New Zealand: 2000-2009. N Z Med J. 2011; 124 (1332): 52-61.
35. Begg K, Roche P, Owen R, et al. Australia's notifi able dis ease status, 2006: annual report of the National Notifi able Diseases Surveillance System. Commun Dis Intell Q Rep. 2008; 32 (2): 139-207.
36. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J. 2007; 26 (3): 238-242.
37. Nieves DJ, Singh J, Ashouri N, McGuire T, Adler-Shohet FC, Arrieta AC. Clinical and laboratory features of pertussis in infants at the onset of a California epidemic. J Pediatr. 2011; 159 (6): 1044-1046.
38. Vaccines and immunizations: pertussis-summary of vaccine recommendations. Centers for Disease Control and Preven tion website. http://www.cdc.gov/ vaccines/vpd-vac/pertussis/recssummary.htm.UpdatedAugust28,2013. AccessedDecember11,2013.
39. Cherry JD. Epidemic pertussis in 2012the resurgence of a vaccine-preventable disease. N Engl J Med. 2012; 367 (9): 785-787.
40. Paisley RD, Blaylock JM, Hartzell JD. Whooping cough in adults: an update on a reemerging infection. Am J Med. 2012; 125 (2): 141-143.
41. Sotir MJ, Cappozzo DL, Warshauer DM, et al. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis. 2007; 44 (9): 1216-1219.
42. Cherry JD. Why do pertussis vaccines fail? Pediatrics. 2012; 129 (5): 968-970.
43. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and dis ease protection. JAMA. 2012; 308 (5): 454-456.
44. Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new? Trends Microbiol. 2012; 20 (5): 211-213.
45. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012; 54 (12): 1730-1735.
46. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection aft er fi ft h dose of acellular pertussis vaccine in children. N Engl J Med. 2012; 367 (11): 1012-1019.
47. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012; 308 (20): 2126-2132.
48. Cornia PB, Hersh AL, Lipsky BA, Newman TB, Gonzales R. Does this coughing adolescent or adult patient have pertussis? JAMA. 2010; 304 (8): 890-896.
49. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005; 18 (2): 326-382.
50. Rutledge RK, Keen EC. Images in clinical medicine. Whoop ing cough in an adult. N Engl J Med. 2012; 366 (25): e39.
51. Pertussis (whooping cough): pertussis (whooping cough) sounds. Centers for Disease Control and Prevention website. http://www.cdc.gov/pertussis/pubs- tools/audio-video.htmlUpdatedAugust28,2013.AccessedNovember25,2013.
52. Taylor ZW, Ackerson B, Bronstein DE, et al. Wheezing in children with pertussis associated with delayed pertussis diagnosis. Pediatr Infect Dis J. 2014; 33 (4): 351-354.
53. Surridge J, Segedin ER, Grant CC. Pertussis requiring intensive care. Arch Dis Child. 2007; 92 (11): 970-975.
54. Irwin RS. Introduction to the diagnosis and management of cough: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129 (1- suppl): 25S-27S.
55. Liu BC, McIntyre P, Kaldor JM, Quinn HE, Ridda I, Banks E. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis. 2012; 55 (11): 1450-1456.
56. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet. 2006; 367 (9526): 1926-1936.
57. Hewlett EL, Edwards KM. Clinical practice. Pertussisnot just for kids. N Engl J Med. 2005; 352 (12): 1215-1222.
58. von König CH, Halperin S, Riff elmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002; 2 (12): 744-750.
59. Pertussis (whooping cough): diagnosis confi rmation. Centers for Disease Control and Prevention website. http://www.cdc.gov/pertussis/clinical/ diagnostic-testing/diagnosis-confirmation.htmlUpdatedJune11,2012. AccessedNovember25,2013.
60. Rosenthal S, Strebel P, Cassiday P, Sanden G, Brusuelas K, Wharton M. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis. 1995; 171 (6): 1650-1652.
61. Young S, Anderson G, Mitchell P. Laboratory observations during an outbreak of pertussis. Clin Microbiol Newsl. 1987; 9 (22): 176-179.
62. Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis. 2001; 183 (9): 1353-1359.
63. Wendelboe AM, Van Rie A. Diagnosis of pertussis: a historical review and recent developments. Expert Rev Mol Diagn. 2006; 6 (6): 857-864.
64. Pertussis (whooping cough): diagnostic testing. Centers for Disease Control and Prevention website. http://www.cdc.gov/pertussis/clinical/ diagnostic-testing/index.htmlUpdatedFebruary24,2011.AccessedNovember12,2013.
65. Centers for Disease Control and Prevention. What's all the whoop about? It's all about pertussis diagnostics [brochure]. Silver Spring, MD: Association of Public Health Laboratories; May 2010.
66. Best practices for health care professionals on the use of polymerase chain reaction (PCR) for diagnosing pertussis. Centers for Disease Control and Prevention website. http://www.cdc.gov/pertussis/clinical/diagnostic-testing/ diagnosis-pcr-bestpractices.htmlUpdatedFebruary18,2011.AccessedNovember27,2012.
67. Mandal S, Tatti KM, Woods-Stout D, et al. Pertussis pseudooutbreak linked to specimens contaminated by Bordetella pertussis DNA from clinic surfaces. Pediatrics. 2012; 129 (2): e424-e430.
68. Reischl U, Lehn N, Sanden GN, Loeff elholz MJ. Real-time PCR assay targeting IS481 of Bordetella pertussis and molecular basis for detecting B ordetella holmesii. J Clin Microbiol. 2001; 39 (5): 1963-1966.
69. Tatti KM, Sparks KN, Boney KO, Tondella ML. Novel multitarget real-time PCR assay for rapid detection of Borde tella species in clinical specimens. J Clin Microbiol. 2011; 49 (12): 4059-4066.
70. Guiso N, Berbers G, Fry NK, He Q, Riff elmann M, Wirsing von König CH; EU Pertstrain group. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis. 2011; 30 (3): 307-312.
71. Pawloski LC, Kirkland KB, Baughman AL, et al. Does tetanusdiphtheria- acellular pertussis vaccination interfere with serodiagnosis of pertussis infection? Clin Vaccine Immunol. 2012; 19 (6): 875-880.
72. Loeff elholz MJ, Sanden GN. Bordetella pertussis. In: Murray PR, Baron E, Jorgensen JH, Landry ML, Pfaller MA, eds. M anual of Clinical Microbiology. Vol 1. 9th ed. Washington, DC: ASM Press; 2007: 803-814.
73. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007; 18 (3): CD004404.
74. Guillot S, Descours G, Gillet Y, Etienne J, Floret D, Guiso N. Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis. 2012; 18 (6): 966-968.
75. Bettiol S, Wang K, Th ompson MJ, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev. 2012; 5 (5): CD003257.
76. Nieves D, Bradley JS, Gargas J, et al. Exchange blood transfusion in the management of severe pertussis in young infants. Pediatr Infect Dis J. 2013; 32 (6): 698-699.
77. Tiwari T, Murphy TV, Moran J; National Immunization Pro gram, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep. 2005; 54 (RR-14): 1-16.
78. Guiso N. Bordetella pertussis and pertussis vaccines. C lin Infect Dis. 2009; 49 (10): 1565-1569.
79. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2012; 3 (3): CD001478.
80. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis. 2013; 56 (9): 1248-1254.
81. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013; 131 (4): e1047-e1052.
82. Mooi FR, Van der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation-two sides of the same coin. Epidemiol Infect. 2014; 142 (4): 685-694.
83. Tefon BE, Özcengiz E, Özcengiz G. Pertussis vaccines: state-of-theart and future trends. Curr Top Med Chem. 2013; 13 (20): 2581-2596.
84. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013; 56 (4): 539-544.
85. Lam ST, George S, Dunlow S, Nelson M, Hartzell JD. Tdap coverage in a military benefi ciary population: room for improvement. Mil Med. 2013; 178 (10): 1133-1136.
86. Kharbanda EO, Parker ED, Nordin JD, Hedblom BD, Rolnick SJ. Infl uenza and pertussis vaccination coverage among privately insured women of reproductive age. Matern Child Health J. 2013; 17 (9): 1631-1637.
87. Centers for Disease Control and Prevention (CDC). Notes from the fi eld: use of tetanus, diphtheria, and pertussis vaccine (Tdap) in an emergency department-Arizona, 2009-2010. MMWR Morb Mortal Wkly Rep. 2012; 61 (3): 55-56.
88. Centers for Disease Control and Prevention (CDC). Nonin fl uenza vaccination coverage among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2013; 62 (4): 66-72.
89. Baratin D, Del Signore C, Th ierry J, Caulin E, Vanhems P. Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010-2011. BMC Public Health. 2012; 12: 940.
90. Böhmer MM, Hellenbrand W, Matysiak-Klose D, Heininger U, Müters S, Wichmann O. Pertussis vaccination coverage among adults in Germany [in German]. Dtsch Med Wochenschr. 2013; 138 (28-29): 1451-1457.
91. National Vaccine Advisory Committee. A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee June 14, 2011. Public Health Rep. 2012; 127(suppl 1): 1-42
92. Centers for Disease Control and Prevention (CDC). Global routine vaccination coverage2012. MMWR Morb Mortal Wkly Rep. 2013; 62 (43): 858-861.
93. Lu PJ, Graitcer SB, O'Halloran A, Liang JL. Tetanus, dipht he ria and acellular pertussis (Tdap) vaccination among healthcare personnel- United States, 2011. Vaccine. 2014;32(5):572-578.
94. Poland GA, Shefer AM, McCauley M, Webster PS, Whitley- Williams PN, Peter G; National Vaccine Advisory Committee, Ad Hoc Working Group for the Development of Standards for Adult Immunization Practices. Standards for adult immunization practices. Am J Prev Med. 2003; 25 (2): 144-150.
95. Community Preventive Services Task Force. The guide to community preventive services. Increasing appropriate vaccination: universally recommended vaccinations. Atlanta, GA: US Department of Health and Human Services, CDC; 2011.
96. Hay JW, Ward JI. Economic considerations for pertussis booster vaccination in adolescents. Pediatr Infect Dis J. 2005; 24 (suppl 6): S127-S133.
97. Terranella A, Asay GR, Messonnier ML, Clark TA, Liang JL. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics. 2013;131(6):e1748-e1756.
98. McGarry LJ, Krishnarajah G, Hill G, et al. Cost-eff ectiveness of Tdap vaccination of adults aged - 65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. PLoS ONE. 2014; 9 (1): e72723.
99. Olyarchuk LD, Willoughby D, Davis SC, Newsom SA. Examining the benefi t of vaccinating adults against pertussis. J Am Acad Nurse Pract. 2012; 24 (10): 587-594.